Skip to main
BNGO

Bionano Genomics (BNGO) Stock Forecast & Price Target

Bionano Genomics (BNGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bionano Genomics exhibited robust growth in its sales of nanochannel array flowcells, with a 17% increase in 2Q25 and a 7% rise in 3Q25 compared to the same periods in the prior year, indicating strong demand for its genomic technologies. The adjusted revenue for consumables, software, and remaining services saw an 11% year-over-year increase in 2Q25, with consumables and software revenues growing by an impressive 16%. Furthermore, the company anticipates new OGM installations to rise for FY2025 to a range of 20-25, compared to the previous expectation of 15-20, reflecting increasing adoption and market expansion efforts, particularly in regions such as Japan.

Bears say

Bionano Genomics faces significant risks that contribute to a negative outlook, primarily stemming from lower-than-anticipated market uptake and utilization of its products and systems. The company may struggle to secure additional capital necessary for its operations, raising concerns about potential dilution for current shareholders. Furthermore, relying on a conservative EV/Revenue multiple combined with projected sales per share indicates only limited upside potential, thereby highlighting the financial challenges ahead for the company.

Bionano Genomics (BNGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bionano Genomics (BNGO) Forecast

Analysts have given Bionano Genomics (BNGO) a Buy based on their latest research and market trends.

According to 3 analysts, Bionano Genomics (BNGO) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bionano Genomics (BNGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.